Faricimab  (Synonyms: RG7716)

Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO)^{[1][2][3][4][5]}.

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

Angiopoietin-2, VEGF-A^[1]

Faricimab (2000 ng/mL, 37 days) to pharmaceutical compounding and storage for up to 37 days has no impairment on its bispecific antigen-binding properties and has a structural integrity of the IgG1 Fc fragment^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Faricimab (10 mg/kg, i.p., twice interval 1 week for 1 or 5 weeks) reduces spontaneous choroidal neovascularization (sCNV), lesion leakage area and subretinal Iba1⁺, CD11b⁺, and CD45⁺ cell infiltration in JR5558 mice^[4].
Faricimab (3 μg/μL, intravitreal injections, a single dose for 48 h) prevents ischemia/reperfusion (I/R) injury-induced retinal permeability and cell death in retinal I/R injury mouse model^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1607793-29-2

Liquid

Colorless to light yellow

[Faricimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa-lambda with half-IG VL-CH1/VH-CK crossover

• 
  Immobilized Faricimab can bind VEGF165 Protein, Human.The EC₅₀ for this effect is 3.418 ng/mL.
• 
  Immobilized Faricimab can bind Human Angiopoietin-2/ANGPT2 Protein (His Tag).The EC₅₀ for this effect is 4.10 ng/mL.

• [1]. Sahni J, et al. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019 Aug;126(8):1155-1170.  [Content Brief]

  [2]. Nicolò M, et al. Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases[J]. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.  [Content Brief]

  [3]. Penha FM, et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME[J]. Int J Retina Vitreous. 2024 Jan 17;10(1):5.  [Content Brief]

  [4]. Canonica J, et al. Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia/reperfusion[J]. Front Cell Neurosci. 2023 Jun 12;17:1192464.  [Content Brief]

  [5]. Jørstad ØK, et al. Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties[J]. Int J Retina Vitreous. 2023 Nov 7;9(1):65.  [Content Brief]